Ring Christine 4
4 · Nurix Therapeutics, Inc. · Filed Jan 30, 2026
Research Summary
AI-generated summary of this filing
Nurix (NRIX) CLO Christine Ring Sells Shares After RSU Vesting
What Happened
- Christine Ring, Chief Legal Officer of Nurix Therapeutics (NRIX), had 10,534 restricted stock units (RSUs convert to one share each) vest and convert to common stock on Jan 30, 2026. A portion of those shares were sold to satisfy tax withholding requirements: 4,333 shares sold at $16.58 (proceeds $71,852) and 88 shares sold at $17.37 (proceeds $1,529), for total proceeds of $73,381. The remaining vested shares were withheld/cancelled to satisfy taxes (reported as conversions/dispositions at $0).
Key Details
- Transaction date: January 30, 2026 (reported same day).
- Vested/converted shares: 10,534 (exercised/converted at $0.00 per share).
- Open-market sales: 4,333 shares @ $16.58 and 88 shares @ $17.37; total proceeds $73,381 (overall weighted avg ≈ $16.60). Reported sale prices ranged from $16.33 to $17.49.
- Shares withheld/cancelled for taxes: 6,113 shares (10,534 vested minus 4,421 sold).
- Footnotes: Sales were mandatory “sell-to-cover” to satisfy tax withholding (not discretionary trades). RSUs represent contingent rights to one share and vest per prior award schedules.
- Shares owned after transaction: not disclosed in this Form 4.
- Filing timeliness: Filed for the reporting period dated Jan 30, 2026; no late filing indicated.
Context
- These transactions reflect RSU vesting and company-mandated sell-to-cover tax withholding rather than an opportunistic open-market trade. In such cases, sales are routine and intended to satisfy withholding obligations rather than signal insider sentiment.
Insider Transaction Report
Form 4
Ring Christine
Chief Legal Officer
Transactions
- Exercise/Conversion
Common Stock
2026-01-30+1,925→ 52,822 total - Exercise/Conversion
Common Stock
2026-01-30+2,000→ 54,822 total - Exercise/Conversion
Common Stock
2026-01-30+3,750→ 58,572 total - Exercise/Conversion
Common Stock
2026-01-30+2,859→ 61,431 total - Sale
Common Stock
[F1][F2]2026-01-30$16.58/sh−4,333$71,852→ 57,098 total - Sale
Common Stock
[F1][F3]2026-01-30$17.37/sh−88$1,529→ 57,010 total - Exercise/Conversion
Restricted Stock Units
[F4][F5][F6]2026-01-30−1,925→ 0 totalExercise: $0.00→ Common Stock (1,925 underlying) - Exercise/Conversion
Restricted Stock Units
[F4][F7][F6]2026-01-30−2,000→ 2,000 totalExercise: $0.00→ Common Stock (2,000 underlying) - Exercise/Conversion
Restricted Stock Units
[F4][F8][F6]2026-01-30−3,750→ 18,750 totalExercise: $0.00→ Common Stock (3,750 underlying) - Exercise/Conversion
Restricted Stock Units
[F4][F9][F6]2026-01-30−2,859→ 25,725 totalExercise: $0.00→ Common Stock (2,859 underlying)
Footnotes (9)
- [F1]The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.
- [F2]Represents the weighted average sale price. The lowest price at which shares were sold was $16.33 and the highest price at which shares were sold was $17.32. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.
- [F3]Represents the weighted average sale price. The lowest price at which shares were sold was $17.33 and the highest price at which shares were sold was $17.49. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.
- [F4]Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.
- [F5]The RSUs will vest in substantially equal increments quarterly over four years, with the first quarterly increment vesting on April 30, 2022, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's Common Stock will be delivered to the Reporting Person following vesting.
- [F6]RSUs do not expire; they either vest or are canceled prior to the vest date.
- [F7]The RSUs will vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2023, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting.
- [F8]The RSUs will vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2024, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting.
- [F9]The RSUs will vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2025, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting.
Signature
/s/ Daniel Burbach, as Attorney-in-Fact for Christine Ring|2026-01-30